{"id":62846,"date":"2026-04-17T05:05:43","date_gmt":"2026-04-17T05:05:43","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/62846\/"},"modified":"2026-04-17T05:05:43","modified_gmt":"2026-04-17T05:05:43","slug":"novo-nordisk-expands-in-china-while-betting-on-ai","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/62846\/","title":{"rendered":"Novo Nordisk expands in China while betting on AI"},"content":{"rendered":"<p>\t\t<img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-1691175 size-large\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/03\/novo-nordisk-obesity-735x490.webp.webp\" alt=\"\" width=\"735\" height=\"490\"  \/>Novo Nordisk is partnering with OpenAI while expanding its sales workforce in China. Photo: Novo Nordisk<\/p>\n<p>Novo Nordisk has entered a strategic partnership with OpenAI to boost drug discovery and development, <a href=\"https:\/\/www.rdworldonline.com\/after-9000-announced-job-cuts-novo-nordisk-taps-openai-as-it-hires-in-china\/\" target=\"_blank\" rel=\"noopener nofollow\">R&amp;D World reports.<\/a><\/p>\n<p>The collaboration will allow Novo Nordisk to analyse massive datasets at a scale previously not possible, with the aim of bringing new treatments to market faster.<\/p>\n<p>The partnership spans research, manufacturing, supply chain and commercial operations, with pilot projects already underway and full integration planned by the end of 2026.<\/p>\n<p>The move comes as Novo Nordisk is restructuring its business, cutting costs and slowing hiring, while facing growing competition in key markets such as China.<\/p>\n<p>At the same time, the company is increasing its presence in China, where many new job openings are focused on sales roles for obesity and diabetes drugs.<\/p>\n<p>The AI push builds on Novo Nordisk\u2019s existing digital efforts, including internal AI tools and partnerships with major tech companies.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk is partnering with OpenAI while expanding its sales workforce in China. Photo: Novo Nordisk Novo Nordisk&hellip;\n","protected":false},"author":2,"featured_media":23955,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1204,694,272],"class_list":{"0":"post-62846","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-artificial-intelligence","9":"tag-medicine","10":"tag-novo-nordisk"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116418309383547521","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/62846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=62846"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/62846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/23955"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=62846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=62846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=62846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}